[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354322-105":59,"doc-detail-354322-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sema6a-inhibits-tumor-progression-and-boosts-anti-tumor-immunity-via-blocking-the-isg15tgf-axis-in-colorectal-cancer","SEMA6A inhibits tumor progression and boosts anti-tumor immunity via blocking the ISG15/TGFβ axis in colorectal cancer","","Semaphorins (SEMAs) are membrane-associated proteins whose dysregulation contributes to cancer, yet their function in colorectal cancer (CRC) is insufficiently defined. This study shows Semaphorin 6A (SEMA6A) is downregulated in CRC, where low expression associates with aggressiveness and poor patient outcomes. SEMA6A overexpression suppresses tumors in vitro and in vivo, and RNA-seq/proteomics identify ISG15 as a key downstream effector. Mechanistically, SEMA6A restrains JAK-STAT3 signaling, reduces ISG15 and thereby limits ISGylation-dependent TGF-β1 stabilization and promotes degradation. Consequently, CD8+ T cell cytotoxicity increases and immune evasion decreases, sensitizing tumors to anti-PD-1 therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sema6a-inhibits-tumor-progression-and-boosts-anti-tumor-immunity-via-blocking-the-isg15tgf-axis-in-colorectal-cancer/354322/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sema6a-inhibits-tumor-progression-and-boosts-anti-tumor-immunity-via-blocking-the-isg15tgf-axis-in-colorectal-cancer/354322.png","ImageObject",300,407,{"name":92,"@type":93},"Aran","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main discovery about SEMA6A in colorectal cancer?","Question",{"text":112,"@type":113},"SEMA6A is downregulated in CRC tissues, and low SEMA6A expression correlates with tumor aggressiveness and poor prognosis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does SEMA6A affect tumor progression experimentally?",{"text":117,"@type":113},"SEMA6A overexpression produces anti-tumor effects in vitro and in vivo.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism links SEMA6A to improved anti-tumor immunity?",{"text":121,"@type":113},"SEMA6A inhibits the JAK-STAT3 pathway, decreasing ISG15 expression, which disrupts ISGylation-dependent stabilization of TGF-β1 and promotes its degradation, thereby enhancing CD8+ T cell cytotoxicity and reducing immune evasion.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354322,1790626822,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455076865,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Zhang et al. Molecular Biomedicine (2026) 7:93 [https://doi.org/10.1186/s43556-026-00493-6](https://doi.org/10.1186/s43556-026-00493-6)  \nMolecular Biomedicine  \n RESEARCH Open Access  \nSEMA6A inhibits tumor progression  \nand boosts anti-tumor immunity via blocking the ISG15/TGFβ axis in colorectal cancer  \nFang Zhang1,2†, Rixin Zhang1,2†, Zheng Yan1,2, Jinbao Zong3,4, Mingxuan Zhou1,2, Tiegang Li1,2, Yufang Hou 1,2, Silin Lv1,2, Zifan Zeng1,2, Wenyi Zhao1,2, Yixin Zhou1,2, Zengni Zhu1,2, Siying Huang1,2 and Min Yang1,2*  \nAbstract  \nSemaphorins (SEMAs) comprise a diverse family of membrane-associated proteins whose dysregulation is implicated in various cancers, influencing tumor progression and immune responses. However, the role of SEMAs in colorectal cancer (CRC) remains underexplored. This study demonstrates that Semaphorin 6A (SEMA6A) is downregulated in CRC tissues, with low SEMA6A expression correlating with increased tumor aggressiveness and poor prognosis in CRC patients. Functional assays illustrate that SEMA6A overexpression exerts anti-tumor effects both in vitro and in vivo, while integrated RNA-seq and proteomic analyses identify ISG15 as a key downstream effector negatively regulated by SEMA6A. Mechanistically, SEMA6A inhibits the JAK-STAT3 pathway, leading to decreased ISG15 expression, which in turn abrogates the ISGylation-dependent stabilization ofTGF-β1 and promotes its degradation, as confirmed by molecular docking, co-immunoprecipitation, and cycloheximide chase assays. Consequently, in vitro co-culture assays and in vivo experiments reveal that SEMA6A overexpression in tumor cells enhances CD8+ T cell cytotoxicity via blocking the ISG15/TGFβ axis. Bioinformatics analyses indicate that patients with CRC exhibiting high SEMA6A and low ISG15 expression show improved responses to immunotherapy. Importantly, SEMA6A overexpression reshapes the tumor microenvironment, boosts anti-tumor immunity of CD8+ T cells and inhibits immune evasion, thereby potentiating anti-PD-1 immunotherapy in vivo. Collectively, these findings highlight the potential of SEMA6A as a dual therapeutic strategy in CRC: inhibiting cancer progression while enhancing anti-tumor immunity by targeting the ISG15/TGF-β1 axis. Thus, SEMA6A represents both a prognostic indicator and a promising target to improve immunotherapy efficacy and enable personalized treatment strategies in CRC.  \nKeywords Colorectal cancer, SEMA6A, Prognosis, Immunotherapy, ISG15  \n†Fang Zhang and Rixin Zhang contributed equally to this work.  \n*Correspondence: Min Yang [minyang@imm.ac.cn](minyang@imm.ac.cn)  \n1 State Key Laboratory of Digestive Health, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 2 Nanwei Road, Beijing 100050, China  \n2 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China  \n3 Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao 266000, China  \n4 Qingdao Hospital of Traditional Chinese Medicine, The Affiliated Qingdao Hiser Hospital of Qingdao University, Qingdao 266033, China  \nIntroduction  \nColorectal cancer (CRC) is a leading cause of cancerrelated mortality worldwide [1, 2]. Early-stage CRC is often asymptomatic, resulting in frequent diagnoses at advanced stages. Early detection and surgical resection significantly improve prognosis, with a 5-year survival rate exceeding 90% for early stages, compared to much lower rates in advanced stages. Consequently, early detection, diagnosis, and intervention are pivotal in CRC management [3]. The advent of multi-omics technologies has enabled the identification of numerous biomarkers, making the discovery of highly specific and sensitive  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, shari","cbCaisQj29R4czjf","https://ap.wps.com/l/cbCaisQj29R4czjf","pdf",4256355,17,"English","# Abstract\n# Introduction","[{\"question\":\"What is the main discovery about SEMA6A in colorectal cancer?\",\"answer\":\"SEMA6A is downregulated in CRC tissues, and low SEMA6A expression correlates with tumor aggressiveness and poor prognosis.\"},{\"question\":\"How does SEMA6A affect tumor progression experimentally?\",\"answer\":\"SEMA6A overexpression produces anti-tumor effects in vitro and in vivo.\"},{\"question\":\"What mechanism links SEMA6A to improved anti-tumor immunity?\",\"answer\":\"SEMA6A inhibits the JAK-STAT3 pathway, decreasing ISG15 expression, which disrupts ISGylation-dependent stabilization of TGF-β1 and promotes its degradation, thereby enhancing CD8+ T cell cytotoxicity and reducing immune evasion.\"}]","SEMA6A inhibits tumor progression and boosts anti-tumor immunity via blocking the ISG15/TGFβ axis in colorectal cancer | PDF",1790110091,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c50e4a7736d92dfc200f8edd76e9090.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/164067ff7b3467cb98eb410f8cc6427e.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c4d62b1750389a6f1a2f01db5a0ef60.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7800ea114b6c61da819cbf738ff6ecb.webp",980,1301]